Cited by 40Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes

Open access
Davidson, Mayer B., Schriger, David L., Peters, Anne L., Lorber, Brett·2000·Journal of General Internal Medicine

Abstract

Objective The Expert Committee on the Diagnosis and Classification of Diabetes retained the 2-hour glucose concentration on an oral glucose tolerance test of >/=11.1 mmol/L (200 mg/dL) as a criterion to diagnose diabetes. Since glycated hemoglobin levels have emerged as the best measure of long-term glycemia and an important predictor of microvascular and neuropathic complications, we evaluated the distribution of hemoglobin A1C (Hb A1C) levels in individuals who had undergone an oral glucose tolerance test to determine how well 2-hour values could identify those with normal versus increased Hb A1C levels.Design A cross-sectional analysis of 2 large data sets was performed. We cross-tabulated 2-hour glucose concentrations on an oral glucose tolerance test separated into 4 intervals (<7.8 mmol/L [140 mg/dL], 7.8-11.0 mmol/L [140-199 mg/dL], 11.1-13.3 mmol/L [200-239 mg/dL], and >/=13.3 mmol/L [240 mg/dL]) with Hb A1C levels separated into 3 intervals (normal; <1% above the upper limit of normal; and greater than or equal to the upper limit of normal + 1%).Results Approximately two thirds of patients in both data sets with 2-hour glucose concentrations of 11.1 to 13.3 mmol/L (200-239 mg/dL) had normal Hb A1C levels. In contrast, 60% to 80% of patients in both data sets with 2-hour glucose concentrations >/=13.3 mmol/L (240 mg/dL) had elevated Hb A1C levels.Conclusion Since Hb A1C levels are the best measures presently available that reflect long-term glycemia, we conclude that the 2-hour glucose concentration criterion on an oral glucose tolerance test for the diagnosis of diabetes should be raised from >/= 11.1 mmol/L (200 mg/dL) to >/= 13.3 mmol/L (240 mg/dL) to remain faithful to the concept that diagnostic concentrations of glucose should predict the subsequent development of specific diabetic complications (e.g., retinopathy).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1525-1497.2000.08024.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 27 · Cited by 40

Research works printed but not linked: 4

  1. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lan- cet. 1976;2:1009-12.
  2. Bucala R, Cerami A, Vlassara H. Advanced glycosylation end products in diabetic complications. Diabetes Rev. 1995;3:258-68.
  3. Cohen MP, Sharma K, Jin Y, et al. Prevention of diabetic nephrop- athy in db/db mice with glycated albumin antagonists. J Clin In- vest. 1995;95:2338-45.
  4. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, im- paired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21:518-24.

Authors
Davidson, M. B., Schriger, D. L., Peters, A. L., & Lorber, B.
Affiliations
  • Charles R. Drew University of Medicine and Science (US)
  • University of California, Los Angeles (US)
Corresponding author
Davidson, Mayer B.
Venue
Journal of General Internal Medicine
Published
2000-08
Volume
15
Issue
8
Pages
551-555
ISSN
  • 0884-8734 (ISSN-L)
  • 1525-1497
OpenAlex
W2076453027
Cited by
40
References
27
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2016: 3 · 2015: 1 · 2014: 3
FWCI
2.18
Type
journal article
Language
en
Open access
Locations
  • Journal of General Internal Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5u01dk054047-06)
  • National Institute of Diabetes and Digestive and Kidney Diseases (5U01 DK54047)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
oral glucose tolerance test, diabetes diagnosis, HbA1c, diagnostic criteria, diabetes complications, retinopathy
MeSH terms
Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Predictive Value of Tests, Reference Values

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review